Pegylated interferon and ribavirin for the treatment of HCV infected patients who failed previous therapy.

被引：0

作者：

Gaglio, PJ ^{[1
]}

Regenstein, F ^{[1
]}

Bartholomew, D ^{[1
]}

Vlacos, M ^{[1
]}

机构：

[1] Tulane Univ, Sch Med, New Orleans, LA 70112 USA

来源：

HEPATOLOGY | 2001年 / 34卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1619

引用

页码：577A / 577A

页数：1

共 50 条

[1] Pegylated interferon and Ribavirin for the treatment of HCV infected patients who failed previous interferon therapy
Gaglio, PJ
Regenstein, FG
Vlacos, MN
Bartholomew, D
Randazzo, P
GASTROENTEROLOGY, 2001, 120 (05) : A384 - A384
[2] Pegylated interferon and Ribavirin for the treatment of HCV patients who failed prior therapy: Racial and genotype differences
Gaglio, PJ
Brown, MJ
Brown, RS
GASTROENTEROLOGY, 2002, 123 (01) : 73 - 73
[3] Treatment with Pegylated Interferon alpha 2b and Ribavirin (rebetol) produces significant sustained virologic response rates in HCV infected patients who failed prior therapy.
Gaglio, PJ
Zimmerman, D
Choi, J
Heller, L
Brown, RS
HEPATOLOGY, 2003, 38 (04) : 318A - 318A
[4] TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL
Lenz, O.
Fevery, B.
Vijgen, L.
Verbeeck, J.
Peeters, M.
Beumont-Mauviel, M.
Zeuzem, S.
Picchio, G.
JOURNAL OF HEPATOLOGY, 2012, 56 : S5 - S5
[5] TMC435 in Patients Infected with HCV Genotype 1 Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Virologic Analyses of The ASPIRE Trial
Picchio, Gaston
Lenz, Oliver
Fevery, Bart
Vijgen, Leen
Verbeeck, Jannick
Peeters, Monika
Beumont-Mauviel, Maria
Zeuzem, Stefan
GASTROENTEROLOGY, 2012, 142 (05) : S145 - S145
[6] Pegylated Interferon (alpha-2B) and ribavirin (Rebetol) for the treatment of HCV infected patients who failed prior therapy: Sustained response data
Gaglio, PJ
Choi, J
Zimmerman, D
Heller, L
Brown, RS
GASTROENTEROLOGY, 2004, 126 (04) : A721 - A721
[7] Treatment with pegylated interferon alpha 2B and ribavirin produces significant sustained virologic response rates in HCV infected patients who failed prior therapy
Gaglio, PJ
Brown, M
Zimmerman, D
Choi, J
Heiler, L
Brown, R
GASTROENTEROLOGY, 2003, 124 (04) : A767 - A767
[8] Safety and efficacy of triple therapy (interferon, ribavirin and amantadine) in the treatment of chronic HCV liver disease patients who previously failed dual therapy.
Lake-Bakaar, GV
GASTROENTEROLOGY, 2000, 118 (04) : A1460 - A1460
[9] Pegylated interferon alpha 2b and Ribavirin for HCV infected patients who failed prior therapy: Interim sustained response data.
Gaglio, PJ
Brown, M
Zimmerman, D
Choi, J
Dove, L
Brown, RS
HEPATOLOGY, 2002, 36 (04) : 575A - 575A
[10] A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
Lawitz, Eric
Rodriguez-Torres, Maribel
Stoehr, Albrecht
Gane, Edward J.
Serfaty, Lawrence
Bhanja, Sanhita
Barnard, Richard J.
An, Di
Gress, Jacqueline
Hwang, Peggy
Mobashery, Niloufar
JOURNAL OF HEPATOLOGY, 2013, 59 (01) : 11 - 17

← 1 2 3 4 5 →